Eli Lilly & Co

LLY
Passed

Company Overview

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Country
US
Market Cap
$553.38B
Last Fiscal Year
2023
Final Shariah Status
Passed
Compliance Analysis Overview

Shariah Compliance Benchmarks:

  • Business Compliance: Non-Shariah compliant revenue must be less than 5% of total revenue
  • Liabilities Compliance: Interest-bearing debt must be less than 33% of market capitalization
Business Compliance
0.22% passed
5% Threshold
0.2%
Liabilities Compliance
4.56% passed
33% Threshold
4.6%
Final Shariah Status
Passed

This stock meets all Shariah compliance criteria according to AAOIFI standards.

Stock Information
Name Eli Lilly & Co
Ticker LLY
Main Business Drug Manufacturers—General
Type Common Stock
Industry Drug Manufacturers—General
Country US
Market Cap $553.38 B

Shariah Analysis Breakdown

Business compliance Breakdown
Revenue Segment Value ($M) Non-Compliant ($M) Reason
Trulicity ® $7,440.0 $0.0 -
Other $6,330.0 $0.0 -
Verzenio ® $2,480.0 $0.0 -
Taltz ® $2,480.0 $0.0 -
Jardiance $2,070.0 $0.0 -
Humalog ® $2,060.0 $0.0 -
COVID-19 Antibodies $2,020.0 $0.0 -
Other products $1,660.0 $0.0 -
Humulin ® $1,020.0 $0.0 -
Cyramza ® $971.4 $0.0 -
Interest income $62.8 $62.8 -
Total $28,594.2 $62.8 0.22% (passed)
Liabilities Compliance Breakdown
Liability Item Value ($M) % of Market Cap
current debt and capital lease obligation $6,900,000,000.0 1.25%
long term debt and capital lease obligation $18,320,000,000.0 3.31%
Total Interest-Bearing Debt $25,220,000,000.0 4.56%
Market Capitalization $553,377,614,400.0 100.00%
Compliance Status Threshold: 33% passed